Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of June 2025. The filing serves to incorporate by reference a press release dated June 30, 2025 (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or detailed financial data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The content is limited to the incorporation of an external press release.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached press release (Exhibit 99.1), the text of which is not included in the input.
Key Facts for Investor Verification
- Verify the specific content of the press release dated June 30, 2025, referenced as Exhibit 99.1, as this filing contains no substantive operational or financial data.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on June 30, 2025.